On average, ADEM and NMOSD/MOGAD presented a longer time of onset (12.5 and 10 days) compared to ATM and MS (6 and 7 days; Figure 4D); interestingly, ATM after mRNA-based vaccines occurred earlier than those following adenoviral-vectored ones (2.5 vs. 8 days), with a similar trend observed in MS relapses (Figure 4E). This evidence concerns the gene ATM and myeloid sarcoma.